Galecto - GLTO Total Company Value-to-Revenue Ratio

Public company logo of galecto.com (GLTO)

Galecto, Inc. (GLTO) is creating a niche monopoly in cancer and fibrosis therapy, which will ensure pricing power, although the company is currently merely surviving on its remaining cash. The EV/Sales ratio helps filter speculative noise from the asset's actual strength, while 0.00 reflects the current level of this metric. Prospects depend on the effectiveness of combating tissue scarring and the availability of funds for testing.

GLTO Galecto, Inc.: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 03/10/2026

Galecto Inc - analytical breakdowns and key metrics (GLTO)

- share price and expert price forecast:
Initial company analysis:Galecto, Inc. - GLTO
Signature product of Galecto

Galecto, Inc. (GLTO) ability to fund clinical trials for galectin-3 inhibitors determines the business's market value, which this metric compares against current sales, excluding the impact of debt load. An analysis of the Enterprise Value to Sales ratio allows an investor to identify growth or stagnation phases, determining the fundamental undervaluation of the asset during periods of market lull to minimize risks while preserving capital.

Competitor analysis for Galecto, Inc.

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|SLNO - Enterprise Value-to-Revenue Ratio|Amicus Pharma (FOLD) - Company Value to Revenue|ETNB: EV/Sales Multiple|AGIO - Total Company Value-to-Revenue Ratio|Company Value to Revenue GPCR|Enterprise Value-to-Revenue Multiple MiMedx MDXG|Enterprise Value-to-Revenue Ratio Rezolute Corp (RZLT)|Company Value to Revenue Lexicon Corp LXRX|Enterprise Value-to-Revenue Ratio MBX Biosciences, Inc. MBX|EV/Sales Multiple altimmune.com ALT|AARD - Enterprise Value-to-Revenue Ratio|Sagimet - Enterprise Value-to-Revenue Coefficient|BioAge Labs Inc. (BIOA) - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume BMEA (Biomea Fusion, Inc.)|QNCX (quincetx.com) - EV/Sales Multiple|GUTS: Business Value to Revenue|Enterprise Value-to-Revenue Ratio vtvtherapeutics.com (VTVT)|ATPC (Agape ATP) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Pluristem Therapeutics PLUR|SYBX: Company Value to Revenue Ratio|lipocine.com - EV/Sales Multiple|Enterprise Value to Sales Volume MTNB|SPRB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)